logo-loader
Allergy Therapeutics PLC

Allergy Therapeutics celebrating 20 years of growth and innovation

Allergy Therapeutics PLC's (LON:AGY) CEO Manuel Llobet and chief financial officer Nick Wykeman discuss with Proactive London's Andrew Scott the group's results for the six months to December 2018.

The company saw turnover rise 10.6% to £46.7mln in the period, up from £42.2mln a year earlier.

2019 is Allergy's 20th anniversary since they spun out of GlaxoSmithKline.

Quick facts: Allergy Therapeutics PLC

Price: £0.13

Market: AIM
Market Cap: £79.52 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Allergy Therapeutics on track for phase III grass pollen trial in 2019

Manuel Llobet, chief executive of Allergy Therapeutics plc (LON:AGY), spoke to Proactive Investors after reporting  “extremely positive results” from the phase II trial of their grass pollen-induced hay fever immunotherapy. Llobet says PQ Grass met its primary endpoint, with those...

on 21/5/18

2 min read